Macrolide-resistant Bordetella pertussis strain identified during an ongoing epidemic, Finland, January to October 2024

Miettinen, Milja; Barkoff, Alex-Mikael; Nyqvist, Aino; Savolainen-Kopra, Carita; Antikainen, Jenni; Mertsola, Jussi; Ivaska, Lauri; He, Qiushui
Macrolide-resistant Bordetella pertussis strain identified during an ongoing epidemic, Finland, January to October 2024

Miettinen, Milja
Barkoff, Alex-Mikael
Nyqvist, Aino
Savolainen-Kopra, Carita
Antikainen, Jenni
Mertsola, Jussi
Ivaska, Lauri
He, Qiushui
Katso/Avaa
Lataukset: 

European Centre for Disease Control and Prevention (ECDC)
doi:10.2807/1560-7917.ES.2024.29.49.2400765
URI
https://doi.org/10.2807/1560-7917.es.2024.29.49.2400765
Näytä kaikki kuvailutiedot
Julkaisun pysyvä osoite on:
https://urn.fi/URN:NBN:fi-fe2025082790208
Tiivistelmä
Since April 2024, a pertussis epidemic has been ongoing in Finland with 2,215 notified cases by end October. Of them, 30.1% (n = 667) were aged 10-14 years. Of the 462 Bordetella pertussis isolates characterised, one was macrolide-resistant (minimum inhibitory concentration (MIC) of erythromycin, azithromycin and clarithromycin > 256 μg/mL). The resistant isolate was serotype FIM2, vaccine antigen pertactin-deficient and harboured ptxP3 allele. The emergence of macrolide-resistant B. pertussis in Europe is worrisome and its rapid identification is important.
Kokoelmat